TriSalus Life Sciences, Inc. TLSI Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 85.1%-0.5pp | 84.6%-1.5pp | 84%-3.1pp | 84.7%-3.0pp | 85.6%-1.1pp | |
| Operating margin | -62.4%+36.6pp | -59.7%+63.2pp | -77.7%+81.5pp | -86.1%+127pp | -99%+156pp | |
| Net margin | -60.9%+23.8pp | -86.9%+15.2pp | -98.4%+108pp | -86.6%+134pp | -84.7%+208pp | |
| EBITDA margin | -61.1%+35.6pp | -58.3%+62.1pp | -76%+80.5pp | -84.1%+126pp | -96.7%+155pp | |
| Free cash flow margin | -45.2%+65.3pp | -41.9%+98.0pp | -55.1%+112pp | -81.3%+144pp | -110.5%+124pp | |
| Returns | ||||||
| Return on assets | -54.8%+62.2pp | -132.3%-8.6pp | -123.8%+58.3pp | -84.5%+160pp | -117%+218pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×-0.5× | 1.5×+0.3× | 1.3×+0.4× | 1×-0.1× | 1.4×+0.2× | |
| Inventory turnover | 1.7×+0.4× | 2×+0.7× | 1.8×+0.5× | 1.5×— | 1.3×-0.5× | |
| Liquidity | ||||||
| Current ratio | 5.8×+3.6× | 2.8×+0.8× | 3.1×+0.7× | 4.1×+1.8× | 2.1×+1.2× | |
| Quick ratio | 5.5×+3.7× | 2.5×+0.9× | 2.8×+0.8× | 3.7×+1.6× | 1.8×+1.1× | |
| Cash ratio | 4.8×+3.7× | 1.8×+0.9× | 2.1×+0.9× | 2.9×+1.5× | 1.1×+0.8× | |
| Leverage | ||||||
| Debt-to-equity | 2.6×— | —— | —— | —— | —— | |
| Debt-to-assets | 0.5×-0.6× | 1×0.0× | 0.9×+0.1× | 0.8×+0.1× | 1.1×— | |
| Interest coverage | -4.9×+2.6× | -4.9×+6.8× | -6.1×+15.1× | -6.4×+53.0× | -7.4×+3,990× | |
| Per Share | ||||||
| Book value per share | $0.24+120% | -$0.89+12.6% | -$0.62+19.5% | -$0.59+44.1% | -$1.20+22.0% | |
| Valuation | ||||||
| Market capitalization | $279.45M+49.6% | $348.75M+128% | $231.88M+110% | $198.61M+50.5% | $172.66M-24.1% | |
| Enterprise value | $255.97M+33.6% | $362.4M+116% | $241.61M+101% | $204.05M+49.6% | $191.01M— | |
| Price / sales | 6.2×+1.0× | 7.7×+2.5× | 5.8×+1.7× | 5.5×+0.2× | 5.4×-5.0× | |
| Price / book | 22.5×— | —— | —— | —— | —— | |
| EV / sales | 5.9×+0.4× | 8×+2.3× | 6×+1.5× | 5.7×+0.2× | 5.9×— | |
| Free cash flow yield | -7%+8.1pp | -5.4%+21.5pp | -9.6%+31.3pp | -14.7%+27.6pp | -20.6%+2.1pp | |
| Earnings yield | -9.5%+6.7pp | -11.2%+8.4pp | -17.1%+33.4pp | -15.7%+25.7pp | -15.8%+12.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are TriSalus Life Sciences, Inc.'s profit margins?
- TriSalus Life Sciences, Inc. (TLSI) runs a 85.1% gross margin and a -62.4% operating margin, with a -60.9% net margin.
- Where do TriSalus Life Sciences, Inc.'s ratios come from?
- Every ratio is computed from TriSalus Life Sciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
